Charles River Labs has a strong history in supporting neuroscience and neurodegenerative diseases across all stages of drug ...

Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...

Such models are not only useful for understanding the underlying causes of disease and identifying new drug targets, but also for drug screening. Patient-derived iPSC models are being used to ...

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, United States ...

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms ... Fossati’s lab to identify ...

Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are ...

Dr. Christopher Seet, an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA, has received a $2.9 million R37 MERIT Award from the National Cancer Institute to ...

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today ...